Providence St. Joseph Health (PSJH) recently launched a new platform to highlight the scholarly activities of its providers, researchers and caregivers: Digital Commons. The institutional repository serves as a singular site to easily access and navigate PSJH journal articles, abstracts, book chapters, presentations and other materials.
Checkpoint inhibitors are showing promise as a potential new line of treatment for people with liver cancer. The Earle A. Chiles Research Institute at Providence Cancer Institute currently has six studies open to liver cancer patients, including two new studies investigating checkpoint inhibitors.
Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute.
The announcement that the Nobel Prize in Medicine has been awarded to two cancer immunotherapy researchers is a significant acknowledgement of the effect of immunotherapy and the work that has been done by the Providence team lead by Walter J. Urba, M.D., Ph.D., director of Earle A. Chiles Research Institute and Robert W. Franz Cancer Center for the last two decades.
The 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center is now open and blessed! This new space allows us to expand and consolidate our outpatient cancer services in the new Providence Cancer Institute Franz Clinic.
PARP inhibitors are emerging as “one of the promising breakthroughs in experimental oncology,” and have the potential to offer significant benefits for women with BRCA-mutant breast cancers.
From groundbreaking research to innovative treatments to compassionate care, everything we do at Providence Cancer Institute is for you, our patients. That's why we have expanded and consolidated outpatient cancer services on the 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center.
PROVIDENCE CANCER INSTITUTE – It is with deep sadness we announce the passing of Elsie Franz Finley who died Aug. 14, 2018. She was 97 years old.
Recent research has opened up new treatment options for advanced bladder cancer and other urothelial cancers, and clinical trials are contributing to the growing knowledge of how checkpoint inhibitors and other immunotherapies can be most beneficial to patients with this difficult-to-treat disease. At Providence Cancer Institute, four new studies of different immunotherapy approaches are now open to patients.
Phase 1 studies are the springboard for advancing new cancer treatments. The Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is often able to offer patients first-in-human clinical trials of immunotherapies and other novel cancer therapies through our own investigator-sponsored trials, and through collaborations with partners across the country.